Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of Bayer Aktiengesellschaft (OTCMKTS:BAYRY) have been given an average recommendation of “Moderate Buy” by the eight brokerages that are currently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, four have given a buy rating and two have issued a strong buy rating on the company.

BAYRY has been the topic of several analyst reports. Barclays raised Bayer Aktiengesellschaft from an “equal weight” rating to an “overweight” rating in a research report on Tuesday, January 6th. Zacks Research cut Bayer Aktiengesellschaft from a “strong-buy” rating to a “hold” rating in a research note on Monday, February 23rd. JPMorgan Chase & Co. raised shares of Bayer Aktiengesellschaft from a “neutral” rating to an “overweight” rating in a report on Monday, December 8th. Morgan Stanley upgraded shares of Bayer Aktiengesellschaft from an “equal weight” rating to an “overweight” rating in a research note on Wednesday, December 3rd. Finally, DZ Bank lowered shares of Bayer Aktiengesellschaft from a “strong-buy” rating to a “strong sell” rating in a research report on Wednesday, February 18th.

Bayer Aktiengesellschaft Trading Down 2.8%

OTCMKTS:BAYRY opened at $11.20 on Friday. The company has a debt-to-equity ratio of 1.10, a current ratio of 1.14 and a quick ratio of 0.71. Bayer Aktiengesellschaft has a one year low of $5.30 and a one year high of $14.85. The company has a market cap of $44.02 billion, a PE ratio of -10.09 and a beta of 0.69. The firm has a 50-day moving average of $12.47 and a 200-day moving average of $9.99.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) last announced its quarterly earnings results on Wednesday, March 4th. The company reported $0.18 earnings per share for the quarter, meeting the consensus estimate of $0.18. The business had revenue of $13.24 billion for the quarter, compared to analysts’ expectations of $13.08 billion. Bayer Aktiengesellschaft had a negative net margin of 8.51% and a positive return on equity of 15.35%. Bayer Aktiengesellschaft has set its FY 2026 guidance at 1.251-1.400 EPS. As a group, equities research analysts expect that Bayer Aktiengesellschaft will post 1.31 EPS for the current fiscal year.

Bayer Aktiengesellschaft Company Profile

Bayer Aktiengesellschaft is a global life sciences company headquartered in Leverkusen, Germany, with a history dating back to 1863. The company operates across three principal business areas—Pharmaceuticals, Consumer Health and Crop Science—serving customers and markets worldwide. Bayer develops, manufactures and markets prescription medicines, over-the-counter healthcare products and agricultural solutions, and maintains research and development programs focused on new therapies and technologies in its core fields.

In Pharmaceuticals, Bayer focuses on prescription drugs across therapeutic areas such as cardiology, oncology, hematology and women’s health, supporting clinical development and regulatory activities for both marketed products and pipeline candidates.